Adeno-associated virus-based vectors in gene therapy

Area of Science:

• Gene Therapy
• Molecular Biology
• Virology

Background:

• Adeno-associated virus (AAV) vectors are promising for gene therapy due to high transduction efficiency in various cell types.
• AAV-mediated gene transfer results in stable, long-term transgene expression without significant immune responses.
• The broad host range of AAV further enhances its potential for therapeutic applications.

Purpose of the Study:

• To review the major benefits and drawbacks of adeno-associated virus (AAV) vectors for gene therapy.
• To discuss recent advances in AAV vector technology over the past three years.
• To evaluate the potential and limitations of AAV vectors in therapeutic contexts.

Main Methods:

• Review of existing literature on adeno-associated virus (AAV) vector technology.
• Analysis of AAV vector properties, including transduction efficiency, immunogenicity, and integration capabilities.
• Discussion of AAV vector limitations such as packaging capacity and production challenges.

Main Results:

• AAV vectors demonstrate efficient transduction of both dividing and non-dividing cells, leading to sustained transgene expression.
• Site-specific integration is possible with transient Rep protein expression, potentially mitigating adverse effects.
• Key limitations include a small packaging capacity (<5 kb) and complex, costly production of recombinant AAV vectors.

Conclusions:

• AAV vectors are powerful tools for gene therapy due to their efficiency, stability, and low immunogenicity.
• Despite limitations in genetic capacity and production, ongoing research and recent advances are improving AAV vector utility.
• Further development is crucial to overcome current challenges and fully realize the therapeutic potential of AAV vectors.